Courtesy of BioMedReports
Missed by most HEB investors were two positive developments. First, Reuters reported that Japan plans to produce enough H1N1 flu vaccine to treat 20 million people by the end of year. The company has been in discussions and testing with that country for some time. “The highest level of the Japanese government and public medical community is now focused exclusively on our product,” Carter told BioMedReports last week. “They stopped working on all other adjuvants (boosters) and are only working with this one because they’ve found that it enhances the vaccines by 100 fold.”
FREE Trend analysis for HEB Here
Then Prohost Biotechnology, an independent publication which evaluates biotechnology companies, their products, technologies, scientists and managers, as well as their finances for fund managers, investors, medical professionals issued a report on Friday calling both Hemispherx’s Ampligen and Antigenics’ (AGEN) QS-21 Stimulon the two most indispensable vaccine adjuvants. “We need adjuvants and Ampligen is among those whom we really need to have available to infectious disease and oncology specialists” said the report.
1 Comment